Apparatuses And Methods For Heart Valve Repair - Patent 7740638 by Patents-189

VIEWS: 7 PAGES: 30

More Info
									


United States Patent: 7740638


































 
( 1 of 1 )



	United States Patent 
	7,740,638



 Hyde
 

 
June 22, 2010




Apparatuses and methods for heart valve repair



Abstract

A medical device for treating a heart having a faulty heart valve is
     disclosed. The medical device comprises a ligature including a first
     anchoring member and a second anchoring member is used. The ligature is
     percutaneously deployable into a patient with a faulty heart valve
     wherein the first anchoring member to anchor to a first tissue area of
     the heart and the second anchoring member to anchor to a second tissue
     area of the heart.


 
Inventors: 
 Hyde; Gregory Mathew (Menlo Park, CA) 
 Assignee:


Abbott Cardiovascular Systems Inc.
 (Santa Clara, 
CA)





Appl. No.:
                    
11/553,105
  
Filed:
                      
  October 26, 2006

 Related U.S. Patent Documents   
 

Application NumberFiling DatePatent NumberIssue Date
 11240589Sep., 2005
 10272060Oct., 20027087064
 

 



  
Current U.S. Class:
  606/139  ; 606/142; 606/144; 606/232
  
Current International Class: 
  A61B 17/10&nbsp(20060101)
  
Field of Search: 
  
  
















 606/72,73,139,144,228,232,99,104,142,143,148,300,304,311,312,325,151
  

References Cited  [Referenced By]
U.S. Patent Documents
 
 
 
3177543
April 1965
Fountain

3716058
February 1973
Tanner, Jr.

4128100
December 1978
Wendorff

4719924
January 1988
Crittenden et al.

4781186
November 1988
Simpson et al.

4817250
April 1989
Kurosaki

4830023
May 1989
de Toledo et al.

4920980
May 1990
Jackowski

4927421
May 1990
Goble et al.

4994067
February 1991
Summers

5040548
August 1991
Yock

5061273
October 1991
Yock

5100418
March 1992
Yoon et al.

5100421
March 1992
Christoudias

5102421
April 1992
Anspach, Jr.

5116337
May 1992
Johnson

5129902
July 1992
Goble et al.

5141520
August 1992
Goble et al.

5156616
October 1992
Meadows et al.

5171233
December 1992
Amplatz et al.

5201598
April 1993
Tehan

5234443
August 1993
Phan et al.

5242456
September 1993
Nash et al.

5246441
September 1993
Ross et al.

5350395
September 1994
Yock

5358479
October 1994
Wilson

5370662
December 1994
Stone et al.

5374275
December 1994
Bradley et al.

5383260
January 1995
Deschenes et al.

5431673
July 1995
Summers et al.

5441483
August 1995
Avitall

5451233
September 1995
Yock

5456667
October 1995
Ham et al.

5487757
January 1996
Truckai et al.

5495974
March 1996
Deschenes et al.

5518162
May 1996
Deschenes et al.

5522873
June 1996
Jackman et al.

5531686
July 1996
Lundquist et al.

5554184
September 1996
Machiraju

5569277
October 1996
Evans et al.

5571215
November 1996
Sterman et al.

5588188
December 1996
Jermyn, Jr.

5609598
March 1997
Laufer et al.

5613937
March 1997
Garrison et al.

5617854
April 1997
Munsif

5626613
May 1997
Schmieding

5632754
May 1997
Farley et al.

5640955
June 1997
Ockuly et al.

5642736
July 1997
Avitall

5681280
October 1997
Rusk et al.

5681346
October 1997
Orth et al.

5682906
November 1997
Sterman et al.

5687723
November 1997
Avitall

5728129
March 1998
Summers

5782828
July 1998
Chen et al.

5810882
September 1998
Bolduc et al.

5823955
October 1998
Kuck et al.

5824008
October 1998
Bolduc et al.

5865800
February 1999
Mirarchi et al.

5868733
February 1999
Ockuly et al.

5868767
February 1999
Farley et al.

5916213
June 1999
Haissaguerre et al.

5954731
September 1999
Yoon

5961440
October 1999
Schweich, Jr. et al.

5964772
October 1999
Bolduch et al.

5972022
October 1999
Huxel

5989284
November 1999
Laufer

6001095
December 1999
de la Rama et al.

6001104
December 1999
Benderev et al.

6001127
December 1999
Schoon et al.

6004332
December 1999
Yoon et al.

6017358
January 2000
Yoon et al.

6021340
February 2000
Randolph et al.

6027514
February 2000
Stine

6036715
March 2000
Yock

6045497
April 2000
Schweich, Jr. et al.

6050936
April 2000
Schweich, Jr. et al.

6051008
April 2000
Saadat et al.

6059715
May 2000
Schweich, Jr. et al.

6077214
June 2000
Mortier et al.

6090096
July 2000
St. Goar et al.

6093199
July 2000
Brown et al.

6110100
August 2000
Talpade

6113609
September 2000
Adams

6117176
September 2000
Chen

6120520
September 2000
Saadat et al.

6123699
September 2000
Webster, Jr.

6149669
November 2000
Li

6161543
December 2000
Cox et al.

6162168
December 2000
Schweich, Jr. et al.

6164283
December 2000
Lesh

6165119
December 2000
Schweich, Jr. et al.

6165120
December 2000
Schweich, Jr. et al.

6165164
December 2000
Hill et al.

6165183
December 2000
Kuehn et al.

6165197
December 2000
Yock

6174323
January 2001
Biggs et al.

6176240
January 2001
Nikolchev et al.

6178346
January 2001
Amundson et al.

6182664
February 2001
Cosgrove

6183411
February 2001
Mortier et al.

6187040
February 2001
Wright

6190401
February 2001
Green et al.

6190408
February 2001
Melvin

6203531
March 2001
Ockuly et al.

6210407
April 2001
Webster, Jr.

6210432
April 2001
Solem

6231561
May 2001
Frazier et al.

6231587
May 2001
Makower

6241728
June 2001
Gaiser et al.

6254568
July 2001
Ponzi

6254598
July 2001
Edwards et al.

6260552
July 2001
Mortier et al.

6261222
July 2001
Schweich, Jr. et al.

6264602
July 2001
Mortier et al.

6267781
July 2001
Tu

6269819
August 2001
Oz et al.

6270526
August 2001
Cox

6283127
September 2001
Sterman et al.

6283962
September 2001
Tu et al.

6299622
October 2001
Snow et al.

6306133
October 2001
Tu et al.

6312447
November 2001
Grimes

6325823
December 2001
Horzewski et al.

6355030
March 2002
Aldrich et al.

6371978
April 2002
Wilson

6374476
April 2002
Ponzi et al.

6402780
June 2002
Williamson, IV et al.

6402781
June 2002
Langberg et al.

6408214
June 2002
Williams et al.

6419696
July 2002
Ortiz et al.

6461366
October 2002
Seguin

6482224
November 2002
Michler et al.

6488689
December 2002
Kaplan et al.

6493575
December 2002
Kesten et al.

6497707
December 2002
Bowman et al.

6500167
December 2002
Webster, Jr.

6517553
February 2003
Klein et al.

6537198
March 2003
Vidlund et al.

6537314
March 2003
Langberg et al.

6551271
April 2003
Nguyen

6554794
April 2003
Mueller et al.

6554852
April 2003
Oberlander

6585718
July 2003
Hayzelden et al.

6599311
July 2003
Biggs et al.

6605086
August 2003
Hayzelden et al.

6610058
August 2003
Flores

6619291
September 2003
Hlavka et al.

6626899
September 2003
Houser et al.

6626930
September 2003
Allen et al.

6629534
October 2003
St. Goar et al.

6638286
October 2003
Burbank et al.

6648903
November 2003
Pierson, III

6656221
December 2003
Taylor et al.

6676702
January 2004
Mathis

6706065
March 2004
Langberg et al.

6709442
March 2004
Miller et al.

6709456
March 2004
Langberg et al.

6712804
March 2004
Roue et al.

6718985
April 2004
Hlavka et al.

6719767
April 2004
Kimblad

6723038
April 2004
Schroeder et al.

6733500
May 2004
Kelley et al.

6746472
June 2004
Frazier et al.

6755812
June 2004
Peterson et al.

6761734
July 2004
Suhr

6764510
July 2004
Vidlund et al.

6770070
August 2004
Balbierz

6790231
September 2004
Liddicoat et al.

6800090
October 2004
Alferness et al.

6810882
November 2004
Langberg

6824562
November 2004
Mathis et al.

6852124
February 2005
Cox et al.

6890353
May 2005
Cohn et al.

6905476
June 2005
Ponzi

6908478
June 2005
Alferness et al.

6911035
June 2005
Blomme

6951549
October 2005
Beyerlein

6960229
November 2005
Mathis et al.

6964683
November 2005
Kowalsky et al.

6966926
November 2005
Mathis

6989028
January 2006
Lashinski et al.

6997951
February 2006
Solem et al.

7073504
July 2006
Callister et al.

7087064
August 2006
Hyde

7104999
September 2006
Overaker

7160318
January 2007
Greenberg et al.

7186264
March 2007
Liddicoat et al.

7247149
July 2007
Beyerlein

7364567
April 2008
Beyerlein

2001/0003986
June 2001
Cosgrove

2001/0005787
June 2001
Oz et al.

2001/0018611
August 2001
Solem et al.

2001/0027322
October 2001
Bowman

2001/0044568
November 2001
Langberg et al.

2002/0010483
January 2002
Folmer et al.

2002/0010486
January 2002
Hirt

2002/0013571
January 2002
Goldfarb et al.

2002/0016628
February 2002
Langberg et al.

2002/0026216
February 2002
Grimes

2002/0035361
March 2002
Houser et al.

2002/0042651
April 2002
Liddicoat et al.

2002/0077647
June 2002
Snow et al.

2002/0087169
July 2002
Brock et al.

2002/0087173
July 2002
Alferness et al.

2002/0103492
August 2002
Kaplan et al.

2002/0103532
August 2002
Langberg et al.

2002/0103533
August 2002
Langberg et al.

2002/0111637
August 2002
Kaplan et al.

2002/0161330
October 2002
Nguyen

2002/0165484
November 2002
Bowe et al.

2002/0165533
November 2002
Flores

2002/0165534
November 2002
Hayzelden et al.

2002/0169502
November 2002
Mathis

2002/0169504
November 2002
Alferness et al.

2002/0183836
December 2002
Liddicoat et al.

2002/0183837
December 2002
Streeter et al.

2002/0183841
December 2002
Cohn et al.

2002/0188170
December 2002
Santamore et al.

2003/0050598
March 2003
Hayzelden et al.

2003/0069593
April 2003
Tremulis et al.

2003/0078465
April 2003
Pai et al.

2003/0083538
May 2003
Adams et al.

2003/0093071
May 2003
Hauck et al.

2003/0105520
June 2003
Alferness et al.

2003/0120340
June 2003
Liska et al.

2003/0120341
June 2003
Shennib et al.

2003/0130731
July 2003
Vidlund et al.

2003/0144697
July 2003
Mathis

2003/0144732
July 2003
Cosgrove et al.

2003/0167071
September 2003
Martin et al.

2003/0171776
September 2003
Adams et al.

2003/0212453
November 2003
Mathis et al.

2003/0216764
November 2003
Tu et al.

2004/0010231
January 2004
Leonhardt et al.

2004/0044350
March 2004
Martin et al.

2004/0044365
March 2004
Bachman

2004/0049207
March 2004
Goldfarb et al.

2004/0059351
March 2004
Eigler et al.

2004/0098092
May 2004
Butaric et al.

2004/0138683
July 2004
Shelton et al.

2004/0138744
July 2004
Lashinski et al.

2004/0148020
July 2004
Vidlund et al.

2004/0153147
August 2004
Mathis

2005/0045183
March 2005
Callister et al.

2005/0055089
March 2005
Macoviak et al.

2005/0085844
April 2005
Tremulis et al.

2005/0209633
September 2005
Callister et al.

2005/0267571
December 2005
Spence et al.

2005/0267573
December 2005
Macoviak et al.

2006/0041306
February 2006
Vidlund et al.

2006/0095025
May 2006
Levine et al.



 Foreign Patent Documents
 
 
 
10161543
Jun., 2003
DE

0377269
Jul., 1990
EP

WO 98/29041
Jul., 1998
WO

WO 99/00059
Jan., 1999
WO

WO 99/13777
Mar., 1999
WO

WO 99/30647
Jun., 1999
WO

WO 99/44534
Sep., 1999
WO

WO 00/03759
Jan., 2000
WO

WO 00/06026
Feb., 2000
WO

WO 00/06027
Feb., 2000
WO

WO 00/06028
Feb., 2000
WO

WO 00/16700
Mar., 2000
WO

WO 00/60995
Oct., 2000
WO

WO 01/00111
Jan., 2001
WO

WO 01/00114
Jan., 2001
WO

WO 01/26557
Apr., 2001
WO

WO 01/28432
Apr., 2001
WO

WO 01/28455
Apr., 2001
WO

WO 01/49213
Jul., 2001
WO

WO 01/49213
Jul., 2001
WO

WO 01/54618
Aug., 2001
WO

WO 01/89440
Nov., 2001
WO

WO 02/00099
Jan., 2002
WO

WO 02/01999
Jan., 2002
WO

WO 02/34167
May., 2002
WO

WO 02/39925
May., 2002
WO

WO 02/053206
Jul., 2002
WO

WO 02/060352
Aug., 2002
WO

WO 02/062263
Aug., 2002
WO

WO 02/062270
Aug., 2002
WO

WO 02/062408
Aug., 2002
WO

WO-02/063533
Aug., 2002
WO

WO-02/078576
Oct., 2002
WO

WO 03/049619
Jun., 2003
WO

WO 03/073913
Sep., 2003
WO

WO 2004/012789
Feb., 2004
WO

WO 2004/014282
Feb., 2004
WO



   
 Other References 

Bonow, R., et al., "Guidelines for the Management of Patients with Valvular Health Disease," Report of American College of Cardiology/American
Heart Assoc. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease), American College of Cardiology and American Heart Assoc., Inc., 1998, pp. 1949-1984. cited by other
.
Messas, et al., "Chordal Cutting: a New Therapeutic Approach for Ischmic Mitral Regurgitation," American Heart Association Inc., 2001, pp. 1958-1963. cited by other
.
PCT Invitation to Pay Additional fees for PCT International Appln. No. US03/36633, mailed May 19, 2004 (5 pages). cited by other
.
PCT Report for PCT International Patent Application PCT/US2004/031403, mailed Jun. 15, 2005. 5 pgs. cited by other
.
Advanced Cardiovascular Systems, Inc., PCT International Preliminary Report on Patentability and Written Opinion for PCT Appln No. US2004/031403, mailed Apr. 13, 2006 (8 pages). cited by other
.
Advanced Cardiovascular Systems, Inc., PCT International Search Report and Written Opinion of the International Searching Authority for PCT Appln No. US2004/031403, mailed May 18, 2005 (15 pages). cited by other
.
Advanced Cardiovascular Systems, Inc., PCT International Search Report for PCT Appln No. US2004/031403, mailed Feb. 15, 2005 (5 pages). cited by other.  
  Primary Examiner: Erezo; Darwin P


  Attorney, Agent or Firm: Feuchtwang; Jonathan
Blakely Sokoloff Taylor & Zafman LLP



Parent Case Text



CROSS-REFERENCE TO RELATED APPLICATIONS


This application is a continuation of co-pending U.S. patent application
     Ser. No. 11/240,589, filed Sep. 29, 2005, which is a divisional of U.S.
     patent application Ser. No. 10/272,060, filed Oct. 15, 2002, now U.S.
     Pat. No. 7,087,064.

Claims  

I claim:

 1.  A medical device comprising: a first anchoring member to anchor to a cardiac tissue and a second anchoring member to anchor to the cardiac tissue;  a ligature coupling the first
anchoring member and the second anchoring member;  a catheter having a size suitable for percutaneous insertion through a blood vessel and the catheter operable to be maneuvered through the blood vessel to the cardiac tissue, the catheter comprising a
proximal end and a distal end and a lumen therethrough, the catheter configured to accommodate the ligature therein;  and a delivery handle coupled to the proximal end of the catheter, wherein the delivery handle comprises a deployment mechanism to
deploy the ligature from the catheter, wherein the delivery handle comprises a first deployment mechanism and a second deployment mechanism wherein the first deployment mechanism is configured for a dedicated deployment of the first anchoring member and
the second deployment mechanism is configured for a dedicated deployment of the second anchoring member.


 2.  The medical device of claim 1, wherein the delivery handle further comprises a first rotating mechanism and a second rotating mechanism wherein the first rotating mechanism can rotate the first anchoring member accommodated at the distal end
of the catheter and the second rotating mechanism can rotate the second anchoring member accommodated at the distal end of the catheter.


 3.  The medical device of claim 1, wherein the catheter further defines a dedicated guidewire lumen extending therethrough.


 4.  The medical device of claim 1, wherein the catheter further defines a first deployment lumen, a second deployment lumen, and a guidewire lumen.


 5.  The medical device of claim 4, further comprising a first deployment shaft coupled to the handle disposed in the first deployment lumen of the catheter and a second different deployment shaft coupled to the handle disposed in the second
deployment lumen of the catheter.


 6.  The medical device of claim 1, wherein a lumen of the catheter may be pressurized to facilitate maneuvering of the catheter.


 7.  The medical device of claim 1, wherein the ligature comprises an elastic material.


 8.  The medical device of claim 1, wherein the ligature has a length that is sufficient to constrict or reduce a size of a heart valve.


 9.  The medical device of claim 1, wherein the ligature is flexible.


 10.  The medical device of claim 1, wherein a length of the ligature is smaller than a diameter of a heart valve.


 11.  The medical device of claim 1, wherein the ligature comprises one of a strap, a string, a cord, a wire, a thread, and a suture.


 12.  A medical device comprising: a ligature comprising an anchoring member at each end, the ligature of a size suitable to constrict or reduce a size of a valve of a heart and each anchoring member operable to couple to tissue and secure the
ligature;  a catheter coupled with the ligature and the catheter having a size suitable for percutaneous insertion through a blood vessel and the catheter operable to be maneuvered through the blood vessel to the heart, the catheter comprising a proximal
end and a distal end and a lumen therethrough a distal portion of which is sized to accommodate the ligature;  a delivery mechanism coupled to the proximal end of the catheter comprising a first deployment shaft to deploy a first anchoring member of the
ligature and a second deployment shaft to deploy a second anchoring member of the ligature;  and a handle coupled to the proximal end of the catheter, further comprising a first deployment mechanism and a second deployment mechanism, wherein the first
deployment mechanism is configured for a dedicated deployment of the first anchoring member and the second deployment mechanism is configured for a dedicated deployment of the second anchoring member.


 13.  The medical device of claim 12, wherein each of the first deployment shaft and the second deployment shaft may be advanced beyond the distal end of the catheter.


 14.  A medical device comprising: a ligature comprising an anchoring member at each end, the ligature of a size suitable to constrict or reduce a size of a valve of a heart and each anchoring member operable to couple to tissue and secure the
ligature;  a catheter coupled with the ligature and the catheter having a size suitable for percutaneous insertion through a blood vessel and the catheter operable to be maneuvered through the blood vessel to the heart, the catheter comprising a proximal
end and a distal end and a lumen therethrough a distal portion of which is sized to accommodate the ligature;  and a delivery mechanism coupled to the proximal end of the catheter comprising a first deployment shaft to deploy a first anchoring member of
the ligature and a second deployment shaft to deploy a second anchoring member of the ligature, wherein the delivery mechanism further comprises a first rotating mechanism and a second rotating mechanism wherein the first rotating mechanism can rotate
the first anchoring member accommodated at the distal end of the catheter and the second rotating mechanism can rotate the second anchoring member accommodated at the distal end of the catheter.  Description 


BACKGROUND OF THE INVENTION


1.  Field of the Invention


The present invention involves a medical device that is used for treating a defective heart valve.


2.  Discussion of Related Art


FIG. 1A illustrates a heart 10.  There are four valves in the heart 10 that serve to direct the flow of blood through the two sides of the heart 10 in a forward direction.  The four valves are a mitral valve 20, an aortic valve 18, a tricuspid
valve 60, and a pulmonary valve 62 as illustrated in FIG. 1A.  The mitral valve 20 is located between the left atrium 12 and the left ventricle 14.  The aortic valve 18 is located between the left ventricle 14 and the aorta 16.  These two valves direct
oxygenated blood coming from the lungs, through the left side of the heart, into the aorta 16 for distribution to the body.  The tricuspid valve 60 is located between the right atrium 22 and the right ventricle 24.  The pulmonary valve 62 is located
between the right ventricle 24 and the pulmonary artery 26.  These two valves direct de-oxygenated blood coming from the body, through the right side of the heart, into the pulmonary artery 26 for distribution to the lungs, where it again becomes
re-oxygenated and distributed to the mitral valve 20 and the aortic valve 18.


All of the heart valves are complex structures.  Each valve consists of moveable "leaflets" that are designed to open and close.  The mitral valve has two leaflets and the tricuspid valve has three.  The aortic and pulmonary valves have leaflets
that are more aptly termed "cusps" and are shaped somewhat like a half-moon.  The aortic and pulmonary valves each have three cusps.


Blood flows into the left ventricle 14 through the mitral valve 20 opens during diastole.  Once the left ventricular cavity has filled, the left ventricle 14 contracts during systole.  The mitral valve 20 closes (the leaflets of the mitral valve
20 re-approximate) while the aortic valve 18 opens during systole allowing the oxygenated blood to be ejected from the left ventricle 14 into the aorta 16.  A normal mitral valve allows blood to flow into the left ventricle and does not allow leaking or
regurgitating back into the left atrium and then into the lungs.  The aortic valve allows blood to flow into the aorta and does not allow leaking (or regurgitating) back into the left ventricle.  The tricuspid valve 60 functions similarly to the mitral
valve to allow deoxygenated blood to flow into the right ventricle 24.  The pulmonary valve 62 functions in the same manner as the aortic valve 18 in response to relaxation and contraction of the right ventricle 24 in moving de-oxygenated blood into the
pulmonary artery and thence to the lungs for re-oxygenation.


With relaxation and expansion of the ventricles (diastole), the mitral and tricuspid valves open, while the aortic and pulmonary valves close.  When the ventricles contract (systole), the mitral and tricuspid valves close and the aortic and
pulmonary valves open.  In this manner, blood is propelled through both sides of the heart.


The anatomy of the heart and the structure and terminology of heart valves are described and illustrated in detail in numerous reference works on anatomy and cardiac surgery, including standard texts such as Surgery of the Chest (Sabiston and
Spencer, eds., Saunders Publ., Philadelphia) and Cardiac Surgery by Kirklin and Barrett-Boyes.


Regurgitation is a condition when leaflets of a heart valve do not completely close causing backflow of blood.  For instance, in a condition typically called mitral valve prolapse, the leaflets of the mitral valve do not close properly and thus,
there is backflow, or regurgitation, of blood into the left atrium and then into lungs.  The heart then has to work harder to pump enough blood for the body, which can lead to heart damage.  Regurgitation is common, and is occurring in about 7% of the
population.  Mitral valve regurgitation is caused by a number of conditions, including genetic defects, infections, coronary artery disease (CAD), myocardial infarction (MI) or congestive heart failure (CHF).  Most cases are mild and if the symptoms are
bothersome, they can usually be controlled with drugs.


In more serious cases, the faulty or defective valve can be repaired with a surgical procedure such as an annuloplasty.  As illustrated in FIG. 1B, an annuloplasty 30 is a surgical procedure in which a synthetic ring 32 is placed around the valve
rim (annulus) 34.  Sutures 38 are put into the valve annulus 34 and the synthetic ring 32.  This causes proper closing by shrinking the size of the valve opening 36.  FIG. 1C illustrates another surgical procedure in which a heart valve such as the
mitral valve 20 is repaired by reconstruction.  First, at step A, a section P2 from the posterior leaflet 40 of the mitral valve 20 is excised.  Then, sequentially at steps B, C, D, and E, sections P1 and P3 of the posterior leaflet 40 are sutured
together.  The reconstruction shrinks the size of the valve opening 36.  In some instances, a faulty or defective valve must be surgically replaced with a new valve.  Examples of new valves include homograft valves (valves harvested from human cadavers),
artificial mitral valves, and mechanical valves.


All of the procedures above are typically major surgical procedures that require the opening of the chest by sternotomy or at best through small incisions in the chest wall, heart lung bypass and stopping the heart beat.  These procedures are
extremely invasive subjecting patients to a lot of pain and discomfort and these procedures require long recovery time and hospitalization time.  In some instances, some patients may not tolerate surgery, for example, due to them having congestive heart
failures.  Thus, having alternative procedures as options to surgery is helpful.


SUMMARY OF THE INVENTION


The present invention discloses apparatuses and methods for treating a defective heart valve.


In one exemplary embodiment of the present invention, a medical device comprises a ligature, including a first anchoring member and a second anchoring member.  The ligature is used to treat a heart having a faulty heart valve (e.g., a faulty
mitral valve).  The ligature is percutaneously deployable into a patient with a faulty heart valve, wherein the first anchoring member anchors to a first tissue area of the faulty heart valve and the second anchoring member anchors to a second tissue
area of the faulty heart valve.  The ligature constricts or reduces the size of the faulty heart valve.


In another exemplary embodiment of the present invention, a medical device comprises a delivery shaft having a delivery lumen, a proximal end, and a distal end.  A first deployment shaft, extending from the proximal end to the distal end, is
disposed within the delivery lumen.  A second deployment shaft, extending from the proximal end to the distal end, is disposed within the delivery lumen.  A ligature is releasably coupled to the delivery shaft.  The ligature includes a first anchoring
member and a second anchoring member.  The delivery shaft deploys the ligature into a patient, wherein the first deployment shaft deploys the first anchoring member to a first tissue area of the patient, and the second deployment shaft deploys the second
anchoring member to a second tissue area of the patient.


In another exemplary embodiment of the present invention, a method of constricting a heart valve of a patient comprises providing a medical device comprising a delivery shaft having a delivery lumen, a proximal end, and a distal end.  The
delivery shaft comprises a first deployment shaft and a second deployment shaft disposed within the delivery lumen.  A ligature including a first anchoring member and a second anchoring member is releasably coupled to the delivery shaft wherein the first
anchoring member is releasably coupled to the first deployment shaft and the second anchoring member is releasably coupled to the second deployment shaft.  The method further comprises deploying the ligature into the patient wherein the first deployment
shaft deploys the first anchoring member to a first tissue area around the heart valve, and the second deployment shaft deploys the second anchoring member to a second tissue area of the heart valve.  Once deployed, the ligature anchors the first
anchoring member to the first tissue area and the second anchoring member to the second tissue area.


In another exemplary embodiment of the present invention, a method of constricting a heart valve of a patient comprises providing a medical device comprising a delivery shaft having a delivery lumen, a proximal end, and a distal end.  The
delivery shaft comprises a first deployment shaft and a second deployment shaft disposed within the delivery lumen.  The method further comprises coupling a first ligature to the delivery shaft and deploying the first ligature to a heart valve area of
the patient and coupling a second ligature to the delivery shaft and deploying the second ligature to the heart valve area of the patient.  Each of the ligatures includes a first anchoring member and a second anchoring member wherein the first anchoring
member is releasably coupled to the first deployment shaft and the second anchoring member is releasably coupled to the second deployment shaft.  The first deployment shaft deploys the first anchoring member to anchor the first anchoring member to the
heart valve area to constrict the heart valve.  The second deployment shaft deploys the second anchoring member to anchor the second anchoring member to the heart valve area to constrict the heart valve. 

BRIEF DESCRIPTION OF THE DRAWINGS


The present invention is illustrated by way of example and not limitation in the figures of the accompanying drawings, in which like references indicate similar elements and in which:


FIG. 1A is an illustration of a heart;


FIG. 1B is an illustration of an annuloplasty procedure to constrict a defective valve;


FIG. 1C is an illustration of a reconstruction procedure to reduce the size of a defective valve;


FIG. 2A is an illustration of an exemplary embodiment of a ligature in accordance with the present invention;


FIG. 2B is an illustration of another exemplary embodiment of a ligature in accordance with the present invention;


FIG. 3 is an illustration of another exemplary embodiment of a ligature in accordance with the present invention;


FIG. 4 is an illustration of an exemplary embodiment of two ligatures being placed across a mitral valve in a parallel pattern to constrict the mitral valve in accordance with the present invention;


FIG. 5 is an illustration of another exemplary embodiment of two ligatures being placed across a mitral valve in an intersecting pattern to constrict the mitral valve in accordance with the present invention;


FIG. 6 is an illustration of an exemplary embodiment of a medical device that includes a delivery device which is used to percutaneously deploy a ligature into a patient to constrict a heart valve;


FIG. 7 is an illustration of a distal end of the medical device shown in FIG. 6 having a ligature disposed therein;


FIG. 8 is an illustration of a mid-section of the medical device shown in FIG. 6;


FIGS. 9-10 are illustrations of a perspective view of the medical device shown in FIG. 6 wherein a ligature is being deployed from the delivery shaft;


FIGS. 11A-11B illustrate another exemplary embodiment of a medical device that includes a delivery device which is used to percutaneously deploy a ligature into a patient to constrict a heart valve;


FIG. 12A is an illustration of an exemplary embodiment of a deployment shaft that can be used to deploy a ligature made in accordance with the present invention;


FIG. 12B is an illustration of an exemplary embodiment of the deployment shaft shown in FIG. 12A being disposed within a deployment lumen of a delivery device;


FIG. 12C is an illustration of an exemplary embodiment of a ligature with helix ends as anchoring members made in accordance with the present invention;


FIG. 12D is an illustration of an exemplary embodiment of the ligature shown in FIG. 12C being disposed within the deployment shaft shown in FIG. 12B;


FIG. 12E is an illustration of an exemplary embodiment of the ligature shown in FIG. 12C being disposed within the deployment shaft shown in FIG. 12B which is disposed within a deployment lumen of a delivery device;


FIGS. 12F-12G are illustrations of a distal end of the medical device shown in FIG. 6 with a ligature having helix ends as anchoring members;


FIGS. 13A-13H are illustrations of an exemplary embodiment of a method to deploy a ligature or ligatures in accordance with the present invention;


FIG. 14A is an illustration of an exemplary embodiment where a medical device made in accordance with the present invention can be inserted percutaneously into a patient to deploy a ligature to a heart valve area;


FIG. 14B is an illustration of another exemplary embodiment where a medical device made in accordance with the present invention can be inserted percutaneously into a patient to deploy a ligature to a heart valve area;


FIG. 14C is an illustration of an exemplary embodiment where a medical device made in accordance with the present invention can be inserted percutaneously into a patient to deploy a ligature to a ventricle area;


FIGS. 15A-15D are illustrations of an exemplary embodiment where a medical device made in accordance with the present invention can be inserted percutaneously into a coronary sinus; and


FIG. 16 is an illustration of an exemplary method of treating heart valve using medical devices made in according with the present invention.


DETAILED DESCRIPTION OF THE PRESENT INVENTION


The present invention pertains to novel medical devices and methods of using these medical devices to treat defective or faulty heart valves.  In the following description, for purposes of explanation, numerous specific details are set forth in
order to provide a thorough understanding of the present invention.  It will be evident, however, to one skilled in the art, that the present invention may be practiced without these specific details.  In other instances, specific apparatus structures
and methods have not been described so as not to obscure the present invention.  The following description and drawings are illustrative of the invention and are not to be construed as limiting the invention.


FIG. 2A illustrates an exemplary embodiment of a medical device that comprises a ligature 100.  The ligature 100 can be a strap, string, cord, wire, bond, thread, suture, or other connector.  The ligature 100 includes a first anchoring member
102A and a second anchoring member 102B.  The ligature 100 serves to link together the first anchoring member 102A and the second anchoring member 102B.  The ligature 100 can be percutaneously deployed into a patient with a faulty heart valve.  By
percutaneous deployment, the ligature 100 is deployed through blood vessels, veins, or arteries into a patient.  In one embodiment, the ligature 100 is deployed through the blood vessels, veins, or arteries and into the heart area of a patient.  The
first anchoring member 102A and the second anchoring member 102B are then attached or anchored to a cardiac tissue (e.g., tissue around the heart valve).  In one embodiment, the first anchoring member 102A and the second anchoring member 102B are not
attached or anchored to a blood vessel, vein, or artery, and only attached or anchored to a cardiac tissue.


A faulty heart valve includes a heart valve that will not properly close causing backflow or regurgitation of blood.  Such a faulty heart valve can be seen in a patient with a condition called regurgitation.  In treating the faulty heart valve,
the first anchoring member 102A anchors to a first tissue area of the faulty heart valve and the second anchoring member 102B anchors to a second tissue area of the faulty heart valve.  The ligature 100 has a length that is sufficient to constrict or
reduce the size of the heart valve once the anchoring members 102A and 102B are anchored into the tissue areas of the heart valve.  Examples of a heart valve that can be treated with the ligature 100 include a mitral valve, an aortic valve, a tricuspid
valve, and a pulmonary valve.


Although the ligature 100 is discussed in relation to treating a faulty heart valve, the ligature 100 may be used to treat other areas of a patient.  For example, the ligature 100 can be used in ventricular remodeling to constrict, reshape, or
reduce, the size of a left ventricle that has been enlarged due to some heart conditions.  Alternatively, the ligature 100 can be used to close a vein or an artery of a patient.


The ligature 100 can be flexible or rigid.  In one embodiment, the ligature 100 is made out of an elastic/resilient material, an elastomeric material, or a superelastic material.  In one embodiment, the ligature 100 is made out of a superelastic
nickel titanium, Nitinol, or stainless steel.  In another embodiment, the ligature 100 is made out of a suture material suitable for suturing a tissue of a patient.  The ligature 100 can be made out of existing suture materials such as polymers like
PTFE, Polyethylene or similar polymers, and resorbable polymers.  The ligature 100 can also be made out of an allograph material such as treated porcine, bovine or human tissue.


In one embodiment, a delivery device, described below, is used to deploy the ligature 100 to a heart to treat a faulty heart valve.  Such a delivery device is able to attach the two anchoring members 102A and 102B of the ligature 100 to two
different attachment sites (e.g., cardiac tissues or tissue areas within or proximate the heart).  The anchoring member 102A is attached to one attachment site and the anchoring member 102B is attached to the other attachment site.  During the attachment
step, the ligature 100 may be stretched so as to reach both attachment sites.  In some cases, the ligature 100 does not need to be stretchable for the anchoring members 102A and 102B of the ligature 100 to anchor into the two different attachment sites. 
After the attachment step, the ligature 100 is able to constrict or reduce the size of the heart valve.  In the embodiment where the ligature 100 is flexible, the ligature 100 is stretched during the attachment step and is returned to its unstretched
length after the attachment step thus, constricting (or reducing) the size of the heart valve.  In the embodiment where the ligature 100 is rigid, the length of the ligature 100 is smaller than the size or the diameter of the heart valve thus, after the
attachment step, the valve can be constricted or reduced.


In one embodiment, multiple ligatures 100 are placed across the faulty heart valve annulus to reshape or reduce the circumference or perimeter of the heart valve annulus.  The ligature 100 may have cross section size that is sufficiently small to
not significantly impede the flow of blood (or other fluid) through the heart valve or produce thrombus.  The ligature 100 may be of a dimension that is similar to surgical sutures known in the field.  The ligature 100 may have a cross section size
between 0.001 mm and 5.0 mm.  The ligature 100 may have a length between 10 mm and 600 mm.  The ligature 100 may have an unstretched length between 10 mm and 600 mm that can be stretched to an appropriate length for deployment purposes and that can be
returned to the unstretched length after the deployment of the ligature 100.


In some cases, the ligatures 100 are placed across a faulty heart valve and left in place for a specific period of time to improve the heart valve function.  In other cases, the ligatures 100 aid in positive remodeling of the left ventricle by
constricting (or reducing) the size of the faulty heart valve annulus so as to relieve the left ventricle from working extra hard to pump blood out of the left ventricle to other areas of the body.  After this remodeling/recovery time a removal system
could be employed at a later date to excise the ligatures 100.


In one embodiment, the ligature 100 has two ends wherein the first anchoring member 102A is attached to one end of the ligature 100 and the second anchoring member 102B is attached to the other end of the ligature 100.  The anchoring members 102A
and 102B are elements that can enter a tissue of a patient body (e.g., a cardiac tissue) and be anchored and retained therein.  FIG. 2A illustrates an exemplary configuration of the anchoring members 102A and 102B, which are referred to as "barbed end"
configurations.  The anchoring members 102A and 102B have pointy ends 106A and 106B.  The anchoring members 102A and 102B may also have a plurality of prongs 108A and 108B.  The pointy ends 106A and 106B allow the anchoring members 102A and 102B to
easily pierce through a tissue wall to begin the anchoring process.  The prongs 108A and 108B prevent the anchoring members 102A and 102B from being detached or released from the tissue thus anchoring the anchoring members 102A and 102B to the tissue
wall.  Each of the anchoring members 102A and 102B has a predetermined length 126A and length 126B, which is dependent upon on the tissue depth that the each of the anchoring members 102A and 102B needs to pierce through to be anchored to the tissue.


The anchoring members of the ligature 100 need not have the configurations shown in FIG. 2A.  Another possible configurations includes a hook-end configuration as shown in FIG. 2B.  The ligature 100 shown in FIG. 2B includes a first hook-end
anchoring member 103A and a second hook-end anchoring member 103B.  The first hook-end anchoring member 103A and the second hook-end anchoring member 103B can anchor the ends of the ligature 100 to a cardiac tissue similar to the anchoring members 102A
and 102B shown in FIG. 2A.


In one embodiment, the anchoring members have a helix end configuration as illustrated in FIG. 3.  In this embodiment, the ligature 100 includes helix ends 104A and 104B.  The helix ends 104A and 104B have ends 105A and 105B that may be pointy,
sharp, or blunt depending on the type of tissue that the helix ends are to be anchored to.  The helix ends 104A and 104B may be continuous helixes made of shape memory material that can maintains the helix ends 104A and 104B in their helical
configuration.  The helix ends 104A and 104B enter the tissue by threading and rotating through the tissue similar to action of a screw.  Each of the anchoring members 104A and 104B has a predetermined length 127A and length 127B, which is dependent upon
on the tissue depth that the each of the helix ends 104A and 104B needs to pierce through to be anchored to the tissue.  In another embodiment, the ligature 100 includes double helix ends (not shown) to increase retentive or anchoring strength.


The anchoring members (e.g., the anchoring members 102A, 102B, 103A, 103B, 104A, and 104B) of the ligature 100 can be made out of metals, plastic, or any other hard materials that are biocompatible or implantable and are suitable for use in a
patient's body.  The anchoring members can also be made out of a semi stiff implantable material.  The anchoring members can be made out of stainless steel, titanium, titanium alloy, nickel, nickel titanium alloy, chroma alloy or other suitable metal
alloys.  The anchoring members can also be made out of polymers, high density polyethylene (HDPE), polyglycolic acid, and polyglycolid hydroxyacetic acid.  In one embodiment, the anchoring members or at least portions of the anchoring members are coated
with a biocompatible lubricious material that provides for easier delivery and entrance into the tissue.


FIG. 4 illustrates an exemplary embodiment where two of the ligatures 100 are placed across a heart valve such as a mitral valve.  In FIG. 4, a heart 202 includes a mitral valve 204, a mitral valve annulus 206, a left fibrous ring 220, a right
fibrous trigone 200 and a left fibrous trigone 210.  The mitral valve 204 may be a faulty mitral valve such as those seen in patients having regurgitation.  In one embodiment, the ligatures 100 (each including anchoring members 102A and 102B) are placed
across the mitral valve 204 in a semi-parallel pattern.  In one embodiment, an anchoring member 102A of a ligature 100 is placed in the left fibrous trigone 210 and an anchoring member 102B is placed in a location on the opposite side of the mitral valve
annulus 206 in the left fibrous ring 220.  Another anchoring member 102A of another ligature 100 is placed in the right fibrous trigone 200 and the other end of another ligature is placed in a location on the opposite side of the mitral valve annulus 206
in the left fibrous ring 220.  If necessary, multiple ligatures 100 may be placed across the mitral valve annulus 206 in a semi-parallel pattern.


FIG. 5 illustrates another exemplary embodiment where two of the ligatures 100 are placed across a heart valve such as a mitral valve.  The placement of the ligatures 100 in FIG. 5 is similar to the placement shown in FIG. 4 except that the
ligatures 100 intersect or cross each other.  In FIG. 5, a heart 202 includes a mitral valve 204, a mitral valve annulus 206, a left fibrous ring 220, a right fibrous trigone 200 and a left fibrous trigone 210.  In one embodiment, the ligatures 100 (each
including anchoring members 102A and 102B) are placed across the mitral valve 204 in an intersecting or cross pattern.  In one embodiment, an anchoring member 102A of a ligature 100 is placed in the left fibrous trigone 210 and an anchoring member 102B
is placed in a location on the opposite side of the mitral valve annulus 206 in the left fibrous ring 220.  Another anchoring member 102A of another ligature 100 is placed in the right fibrous trigone 200 and the other end of this ligature 100 is placed
in a location on the opposite side of the mitral valve annulus 206 in the left fibrous ring 220.  If necessary, multiple ligatures 100 may be placed across the mitral valve annulus 206 in the intersecting or cross pattern.


It is to be appreciated that the semi parallel and the intersecting patterns can be combined together for the placements of the ligatures 100 if necessary.  Additionally, the anchoring members of the ligatures shown in FIGS. 4 and 5 can have
barbed end configurations as those shown for the anchoring members 102A or 102A, helix ends 104A or 104B, as those shown in FIG. 3 or hook ends 103A and 103B as those shown in FIG. 2B, or other types of ends that will anchor the ends of the ligature 100
to a tissue or a cardiac tissue.  Also, a ligature 100 may include more than one anchoring member at each end of the ligature 100.


FIG. 6 illustrates a perspective view of one exemplary embodiment of a medical device 301 that includes a ligature 100 which can be used to percutaneously deploy a ligature 100 to a heart to treat a faulty heart valve.  FIG. 7 illustrates a cross
section "A" of the distal end 324 of the medical device 301.  FIG. 8 illustrates a cross section "B" of the mid-section of the medical device 301.


In one embodiment, the medical device 301 comprises a delivery shaft 300 having a delivery lumen 305 (FIGS. 7-8), a proximal end 322, and a distal end 324.  In one embodiment, the delivery shaft 300 is a catheter, which is sized and shaped as
generally known in the art to travel within and along the vascular tree to the heart of a patient.  A first deployment shaft 310A and a second deployment shaft 310B are disposed within the delivery lumen 305 and extend from the distal end 324 to the
proximal end 322.  A ligature 100 is releasably coupled to the delivery shaft 300 at the distal end 324 such that the ligature 100 is coupled to the delivery shaft 300 for deployment, and after deployment, the ligature 100 is released from the delivery
shaft 300.  The ligature 100 includes a first anchoring member 102A and a second anchoring member 102B and the ligature 100 links them as previously described.  The medical device 301 can deploy the ligature 100 into a patient wherein the first
deployment shaft 310A deploys the first anchoring member 102A to a first tissue area of the patient (e.g., a cardiac tissue, a tissue proximate a mitral valve, or a portion of the mitral valve) and the second deployment shaft 310B deploys the second
anchoring member 102B to a second tissue area of the patient (e.g., another cardiac tissue, another tissue proximate a mitral valve, or another portion of the mitral valve).


In one embodiment, the ligature 100 is contained in the distal end 324 of the delivery shaft 300 near the cross section "A." The delivery lumen 305 may be a dumbbell shaped lumen 305.  The dumb bell shaped lumen 305 provides a compartment in the
distal end of the delivery shaft 300 where the ligature 100 can reside undisturbed as the medical device 301 is advanced to an area of the heart to be treated.


In one embodiment, the ligature 100 is housed inside the delivery lumen 305 on the distal end 324.  The anchoring member 102A of the ligature 100 is mounted on the distal end of the deployment shaft 310A; and, the anchoring member 102B is mounted
on the distal end of the deployment shaft 310B.  In one embodiment, the deployment shaft 310A is housed in its own deployment lumen 306 and the deployment shaft 310B is housed in its own deployment lumen 308.  The deployment lumens 306 and 308 may
combine together to form the dumb bell shape lumen 305 or may be two separate lumens comprised within the delivery shaft 300.  The delivery lumen 305 does not need to (but may) maintain its dumb bell shape for the entire length of the delivery shaft 300
or may only have the dumb bell shape at the distal end 324 of the delivery shaft 300.  The delivery shaft 300 may include additional lumens such as additional lumens for the delivery of additional ligatures or for sensing endoscopy or to allow a pull
wire to be used to deflect the distal end 324 (in order to control the positions where the anchoring members are anchored).


In one embodiment, the delivery shaft 300 is further coupled to a handle member 340, which is used in deploying the ligature or ligatures 100 as shown in FIG. 6.  The handle member 340 includes a deployment mechanism 350A and a deployment
mechanism 350B, which can advance or retract the deployment shafts 310A and 310B, respectively, to deploy the ligature 100.  In one embodiment, the proximal end of the deployment shaft 310A is connected to the deployment mechanism 350A.  The proximal end
of the deployment shaft 310B is connected to the deployment mechanism 350B.


In one embodiment, the delivery shaft 300 also includes a guide wire lumen 320 as shown in FIGS. 7-8.  The guide wire lumen 320 extends from the distal end 324 of the delivery shaft 300 to the proximal end 322 of the delivery shaft 300, through
the handle member 340, and is connected to a guide wire port 360 in the proximal end of the handle member 340.  The guide wire lumen 320 is sufficiently sized and shaped to allow for the insertion of a guide wire (not shown).  The guide wire may be
disposed through the guide wire lumen 320 to guide or maneuver the delivery shaft 300 from the entrance of the patient's body through the body of the patient to reach the area of the heart where the ligature 100 will be deployed, e.g., a mitral valve. 
In one embodiment, the guide wire port 360 is used to control the advancement, movement, or steering of the guide wire through the patient's body.


In one embodiment, the delivery shaft 300 may include reinforcement member such as a plurality of strands disposed in braided pattern, a plurality of fibers kitted together, or a coiled wire (not shown).  In another embodiment, the delivery shaft
300 may comprise other lumens or supporting member (not shown) that can be used to steer or aim the distal end 324 of the medical device 301 in a desired direction.  These supporting members may be of a pre-shaped nature curving the delivery shaft 300 as
the supporting members are advanced within a lumen to the distal end 324 of the delivery shaft 300.  One or more of these steering lumen and supporting member may be present in the delivery shaft 300.


In another embodiment, a supporting member may consist of a member (not shown) that is coupled to the distal end 324 of a steering lumen included within the delivery shaft 300.  The steering lumen can be the guidewire lumen 320 shown in FIGS.
7-8.  The supporting member may extend from the distal end 324 to the proximal end 322 of the delivery shaft 300.  In one embodiment, pulling on this supporting member at the proximal end 322 causes the distal end 324 of the delivery shaft to become
curved.  In another embodiment, the steering lumen is pressurized causing the distal end 324 of the delivery system to bend in a desired direction.


In one embodiment, the guide wire lumen 320 may only be present in the distal end 322 of the delivery shaft 300 as in common rapid exchange catheter design known in the art.  A common rapid exchange catheter is well known in the art.  In another
embodiment, the guide wire lumen 320 may absent from the delivery shaft 300 and may be replaced by one or more tendons to produce a bendable tip delivery shaft 300.


The delivery shaft 300 may be made out of numerous different types of materials.  In one embodiment, the delivery shaft 300 is made out of materials that are suitable for inserting into a patient's body.  For example, the delivery shaft 300 may
be made out of materials suitable for making a catheter.  The delivery shaft 300 may be made out of polyether block amid (PEBA), polyethylene (PE), polyproplylene (PP), polyvinylchloride (PVC), polytetrafluoroethylene (PTFE), or polyurethane, or other
types of biocompatible material.


In one embodiment, the delivery shaft 300 comprises at least one radiopaque marker to aid the operator (e.g., a physician) in the monitoring, placing, or inserting of the delivery shaft 300 into a patient.  The radiopaque marker can be a band of
radiopaque material disposed proximate the distal end 324 of the delivery shaft 300.  The radiopaque material aids the operator in determining the location of the distal end 324 of the delivery shaft 300.  Examples of a radiopaque material include gold,
platinum, tungsten, iron, silver, and thermoplastic material loaded with a radiopaque filler such as barium sulfate, bismuth subcarbonate, bismuth trioxide, bismuth oxychloride, tungsten power, and depleted uranium, etc. In another embodiment, the
delivery shaft 300 comprises at least one Magnetic Resonance Imaging (MRI) marker to aid the operator in the monitoring, placing, or inserting of the delivery shaft 300 into a patient.  An example of an MRI marker materials include platinum, tungsten,
iridium, barium sulfate, plastic, or other particles suitable for a MRI process.  Alternatively, the MRI marker can be an active component such as a small circuit that can generate a radio frequency (RF) that an MRI scanner can detect.


FIG. 9 illustrates a perspective view of the medical device 301 wherein the delivery shaft 300 is deploying the ligature 100 that is releasably coupled to the delivery shaft 300.  In one embodiment, the medical device 301 is used to deploy the
ligature 100 to place the ligature 100 across the mitral valve as illustrated in FIG. 4-5.  The medical device 301 can be used to deploy the ligature 100 to other area of the heart, for example, within a coronary sinus (see FIG. 15A) or over the left
ventricle of the heart (see FIGS. 14B and 14C).


In one embodiment, advancing the deployment shaft 310A advances the anchoring member 102A of the ligature 100 out of the delivery shaft 300 as illustrated in FIG. 9.  As the deployment shaft 310A is advanced, the anchoring member 102A is advanced
from the lumen 305 at the distal end 324 of the delivery shaft 300 to a tissue area 326.  Once the anchoring member 102A is anchored to the tissue area 326, the deployment shaft 310A can be retracted into the delivery shaft 300 leaving the anchoring
member 102A embedded in the tissue area 326.  In one embodiment, the deployment shaft 310A is retracted as illustrated in FIG. 10 wherein the anchoring member 102A is left attached or anchored to the tissue area 326.  This process can be repeated for the
anchoring member 102B of the ligature 100.  The deployment shaft 310B is advanced out of the delivery shaft 300 thus advancing the anchoring member 102B.  In one embodiment, the anchoring member 102B is anchored to a tissue area 328 which can be
substantially opposite the tissue area 326 where the anchoring member 102A is anchored.  Once the anchoring member 102B is anchored into the tissue area 328, the deployment shaft 310B is retracted into the delivery shaft 300.


In the embodiment where the ligature 100 is flexible, once both of the anchoring members 102A and 102B of the ligature 100 are anchored, the ligature 100 is allowed to return to its original length (unstretched length) or its original shape,
thus, bringing the tissue areas 326 and 328 closer to each other.  When the tissue areas 326 and 328 are brought closer to each other, the heart structure that the ligature 100 is placed across, e.g., the mitral valve, is narrowed, reduced, or
constricted.  In the embodiment where the ligature 100 is made of a rigid material, once the anchoring members 102A and 102B of the ligature 100 are anchored, the ligature 100 pull the tissue areas 326 and 328 are closer to each other.  Again, when the
tissue areas 326 and 328 are brought closer to each other, the heart structure that the ligature 100 is placed across, e.g., the mitral valve, is narrowed, reduced, or constricted.


The medical devices 301 shown in FIGS. 6-8 and 9-10 include the ligature 100 that has barbed end configurations for the anchoring members 102A and 102B.  It is to be appreciated that the anchoring members 102A and 102B may have other
configurations, for examples, helixes, or hooks as shown in FIGS. 2B and 3.


FIGS. 11A-11B illustrate an exemplary medical device 302.  The medical device 302 is similar to the medical device 301 except that the device 302 is more preferred for delivering a ligature 100 that has helix ends as the anchoring members.  As
illustrated in FIGS. 11A-11B, the medical device 302 comprises a delivery shaft 303 having a delivery lumen 318, a proximal end 332, and a distal end 334.  In one embodiment, the delivery shaft 303 is a catheter, which is sized and shaped as generally
known in the art to travel within and along the vascular tree to the heart of a patient.  In another embodiment, the delivery shaft 303 is the same as the delivery shaft 300.


In one embodiment, a first deployment shaft 307 and a second deployment shaft 309 are disposed within the delivery lumen 318 and extended from the distal end 334 to the proximal end 332.  A ligature 100 is releasably coupled to the delivery shaft
303 at the distal end 334 such that the ligature 100 is coupled to the delivery shaft 303 for deployment, and after deployment, the ligature 100 is released from the delivery shaft 303.  The ligature 100 includes a first anchoring member 104A and a
second anchoring member 104B which are of helix ends.  The medical device 302 can deploy the ligature 100 into a patient wherein the first deployment shaft 307 deploys the first anchoring member 104A to a first tissue area of the patient (e.g., a cardiac
tissue, a tissue proximate a mitral valve, or a portion of the mitral valve) and the second deployment shaft 309 deploys the second anchoring member 104B to a second tissue area of the patient (e.g., a cardiac tissue, a tissue proximate a mitral valve,
or a portion of the mitral valve).


In one embodiment, the ligature 100 is contained in the distal end 334 of the delivery shaft 303.  The delivery lumen 318 may be a dumbbell shaped lumen 318.  The dumb bell shaped lumen 318 provides a compartment in the distal end of the delivery
shaft 303 where the ligature 100 can reside undisturbed as the medical device 302 is advanced through the patient's vasculature to an area of the heart to be treated.


In one embodiment, the ligature 100 is housed inside the delivery lumen 318 on the distal end 334.  The anchoring member 104A of the ligature 100 is mounted on the distal end of the deployment shaft 307; and, the anchoring member 104B is mounted
on the distal end of the deployment shaft 309.  In one embodiment, the deployment shaft 307 is housed in its own deployment tube 336 and the deployment shaft 308 is housed in its own deployment tube 338 as illustrated in FIG. 11B.  The deployment tubes
336 and 338 may combine together to form the dumb bell shape lumen 318 or may be two separate tubes disposed within the delivery shaft 303.  The delivery lumen 318 does not need (but may) maintain its dumb bell shape for the entire length of the delivery
shaft 303 or may only have the dumb bell shape at the distal end 334 of the delivery shaft 303.


In one embodiment, the delivery shaft 303 is further coupled to a handle member 304, which is used to deploy the ligature or ligatures 100.  The handle member 304 includes a deployment mechanism 350A and a deployment mechanism 350B, which can
advance or retract the deployment shafts 307 and 309, respectively, to bring the ligature 100 closer to the anchoring sites.  In one embodiment, at least a section near the proximal end of the deployment shaft 307 is connected to the deployment mechanism
350A.  A section near the proximal end of the deployment shaft 309 is connected to the deployment mechanism 350B.  In one embodiment, as the deployment shafts 309 and 309 are advanced or retraced, the anchoring members 104A and 104B of the ligature 100
are advanced or retracted.


The handle member 304 also includes a rotating mechanism 314 and a rotating mechanism 316, which can rotate the deployment shafts 307 and 309 as the deployment shafts 307 and 309 are advanced or retracted.  In one embodiment, the proximal end of
the deployment shaft 307 is connected to the rotating mechanism 314.  The proximal end of the deployment shaft 309 is connected to the rotating mechanism 316.  In one embodiment, rotating the rotating mechanism 314 rotates the deployment shaft 307 thus
rotating the anchoring member 104A.  Similarly, rotating the rotating mechanism 316 rotates the deployment shaft 309 thus rotating the anchoring member 104B.


In one embodiment, the deployment tubes 336 and 338 are connected to the deployment mechanisms 350A and 350B, respectively.  In this embodiment, the deployment tubes 336 and 338 are advanced or retracted by the deployment mechanisms 350A and
350B.  As the deployment tube 336 and 338 are advanced or retracted, the deployment shafts 307 and 309 are also advanced or retracted.  Thus, in this case, to deploy the anchoring members 104A and 104B, the deployment mechanisms 350A and 350B advance the
deployment tubes 336 and 338, respectively.  The deployment tubes 336 and 338 may be advanced completely out of the delivery shaft 303 or may only be partially advanced.  Then, the deployment shafts 307 and 309 are then rotated by the rotating mechanisms
314 and 316, respectively to deploy the anchoring members 104A and 104B.


In one embodiment, the delivery shaft 303 also includes a guide wire lumen 312 as illustrated in FIGS. 11A-11B.  The guide wire lumen 312 extends from the distal end 334 of the delivery shaft 303 to the proximal end 332 of the delivery shaft 303,
and through the handle member 304 and is connected to a guide wire port 330 located at the proximal end of the handle member 304.  The guide wire lumen is sufficiently sized and shaped to allow for the insertion of a guide wire (not shown).  The guide
wire may be disposed through the guide wire lumen 312 to guide or maneuver the delivery shaft 303 through the body of the patient to reach the area of the heart where the ligature 100 is to be deployed, e.g., a mitral valve.  In one embodiment, the guide
wire port is used to control the advancement, movement, or steering of the guide wire through the patient's body.


In one embodiment, the delivery shaft 303 may include reinforcement member similar to the delivery shaft 300 described above.  In another embodiment, the delivery shaft 303 may comprise other lumens or supporting member that can be used to steer
or aim the distal end 334 of the medical device 302 in a desired direction.  These supporting members may be of a pre-shape nature curving the delivery shaft 303 as the supporting members are advanced within a lumen to the distal end 334 of the delivery
shaft 303.  One or more of these steering lumen and supporting member may be present in the delivery shaft 303.


In another embodiment, a supporting member may consist of a member (not shown) that is coupled to the distal end 334 of a steering lumen included within the delivery shaft 303.  The steering lumen can be the guidewire lumen 312 shown in FIGS.
11A-11B.  The supporting member may extend from the distal end 334 to the proximal end 332 of the delivery shaft 303.  In one embodiment, pulling on this supporting member at the proximal end 332 causes the distal end 334 of the delivery shaft to become
curved.  In another embodiment, the steering lumen is pressurized causing the distal end of the delivery system to bend in a desired direction.


In one embodiment, the guide wire lumen 312 may only be present in the distal end 332 of the delivery shaft 303 as in common rapid exchange catheter design as is known in the art.  In another embodiment, the guide wire lumen 312 may absent from
the delivery shaft 303 and may be replaced by one or more tendons to produce a bendable tip delivery shaft 303.


The delivery shaft 303 may made out of numerous different types of materials similar to the material used to make the delivery shaft 300 described above.  Also, similar to the delivery shaft 300, the delivery shaft 303 may also comprise at least
one radiopaque marker or an MRI marker to aid the operator (e.g., a physician) in the monitoring, placing, or inserting of the delivery shaft 303 into a patient.


FIGS. 12A-12G illustrate an exemplary deployment shaft that can be used with the medical device 302 to deploy the ligature 100.  The deployment shaft can be the deployment shaft 307 or 309 shown in FIGS. 11A-11B.  In one embodiment, the
deployment shaft 307 shown in FIG. 12A is disposed within the deployment tube 336 as shown in FIG. 12B.  In one embodiment, the deployment shaft 307 includes a slot 342 wherein a portion of the ligature 100 can reside until deployment.  The slot 342 is
useful in that it helps keep the ligature 100 from being entangled between two deployment shafts 307 and 309.  The slot 342 is not necessary for the deployment shaft 307 or 309 to function properly in deploying the ligature 100.


In one embodiment, a portion of the ligature 100 proximate the anchoring member 104A is spiraled around the deployment shaft 307 (as shown in FIG. 12D); and, the other portion of the ligature 100 proximate the anchoring member 104B would be
spiraled around the deployment shaft 309 in a similar manner (not shown).  In the embodiment where the deployment shafts 307 and 309 each includes a slot 342, the portion of the ligature 100 that is not wound around the deployment shafts 307 and 309
extends through the slot 342.  The ligature 100 extending from one slot 342 of one deployment shaft (e.g., deployment shaft 307) can be inserted into another slot 342 on another deployment shaft (e.g., deployment shaft 309).


In one embodiment, the distal end of the deployment shaft 307 further comprises an axis 344 such that the helix anchoring member 104A can be kept there or releasably coupled thereto until the deployment of the ligature 100.  The deployment shaft
307 with the ligature 100 releasably coupled thereto can be disposed within the deployment tube 336 as illustrated in FIG. 12E.  FIGS. 12F-G further illustrates the distal end 334 of the delivery shaft 302 wherein the deployment shafts 307 and 309 are
disposed within the deployment tube 336 and 338, respectively.


It is to be appreciated that a similar construction to the deployment shaft 307 can used for the ligature 100 with the barbed end configurations for the anchoring member 102A and 102B described above.  In this embodiment, the barbed end will be
kept at the axis 344 until after deployment.


FIGS. 13A-13H illustrate an exemplary process of deploying the ligature 100 that includes helix ends anchoring members.  At FIGS. 13A-13B, the deployment tube 336 is advanced in order to advance the deployment shaft 307 (not visible in these
figures) toward a tissue area 344.  Advancing the deployment shaft 307 would advance the helix ends 104A toward the tissue area 344.  In one embodiment, the deployment tube 336 is advanced toward the tissue area 344 by a deployment mechanism, such as the
deployment mechanism 350A shown in FIG. 11.  After the advancement, the deployment shaft 307 is then rotated by a rotating mechanism such as the rotating mechanism 314 shown in FIG. 11.  In this case, the linkage portion of the ligature 100 which joins
the two anchoring members, the helix ends 104A and 104B, is flexible and twistable so that one helix end can be rotated while the other helix end is not.  As the deployment shaft 307 is rotated, the helix end 104A is also rotated allowing it to pierce
through the tissue area 344 as illustrated in FIG. 13C.  In one embodiment, upon advancing, the helix end 104A is rotated in a direction that would enhance the advancement of the helix end 104A into the tissue area 344.  The rotation of the deployment
shaft 307 is initiated by a rotation of the rotating mechanism.  Once the helix end 104A is anchored to the tissue area 344, the deployment tube 336 together with the shaft 307 is retracted into the delivery shaft 303 leaving the helix end 104A embedded
(or anchored) in the tissue area 344 as illustrated in FIG. 13D.  This process can be repeated for the helix end 104B of the ligature 100.


As shown in FIGS. 13D-13E, the deployment tube 338 is advanced out of the delivery shaft 303 to advance the deployment shaft 309 to a tissue area 346.  Advancing the deployment shaft 309 would advance the helix end 104B toward the tissue area
346.  After the advancement, the deployment shaft 309 is rotated by a rotating mechanism such as the rotating mechanism 316 shown in FIG. 11.  As the deployment shaft 309 is rotated, the helix end 104B is also rotated allowing it to pierce through the
tissue area 346 as illustrated in FIGS. 13E-F. In one embodiment, upon advancing, the helix end 104B is rotated in a direction that would enhance the advancement of the helix end 104B into the tissue area 346.  Once the helix end 104B is anchored to the
tissue area 346 as shown in FIG. 13F, the deployment shaft 309 is retracted into the delivery shaft 303 leaving the helix end 104B embedded in the tissue area 346 as illustrated in FIGS. 3G-H.


After the helix ends 104A and 104B are anchored to the tissue area 344 and 346, respectively, the delivery shaft 303 may then be retracted from the tissue area 344 and 346.  The process described in FIGS. 13A-13H may be repeated as needed to
deploy as many ligatures 100 as necessary.  In one embodiment, the process is used to constrict a heart valve such as a mitral valve by placing multiple ligatures 100 across the mitral valve's annulus.  In one embodiment, the tissue area 344 and 346 are
the fibrous tissue around the annulus of the mitral valve.  The anchoring of the helix ends 104A and 104B thus places the ligature 100 across the heart valve to reduce or constrict the size of the heart valve.  The ligatures 100 with the helix ends can
be placed across the mitral valve using this process to place the ligatures 100 similarly to what is depicted in FIGS. 4 and 5.


FIG. 14A illustrates an exemplary route of percutaneously inserting the ligatures 100 into a patient's heart 110.  As previously mentioned, by percutaneous deployment, the ligature 100 is deployed through blood vessels, veins, or arteries into a
patient.  In one embodiment, the ligature 100 is deployed through the blood vessels, veins, or arteries and into the heart area of a patient.


In one embodiment, FIG. 14A illustrates an exemplary route of percutaneously inserting the ligatures 100 into the heart 110 and placing the ligatures 100 across the mitral valve 120 of the heart 110.  In one embodiment, a medical device
containing the ligature 100 is introduced into the patient's body percutaneously using a modified Seldinger technique in which the medical device is inserted into the venous vascular tree through the femoral vein.  In one embodiment, the medical device
enters or reaches the annulus of the mitral valve 120 from the atrial side of the heart 110.  A medical device 130 is first provided.  The medical device 130 can be the medial device 301 or the medical device 302 described above.  The medical device 130
can also be a catheter capable of delivering and deploying a ligature 100 to the heart.  The medical device 130 is advanced up the inferior vena cava (IVC) 122 and into the right atrium (RA) 112 of the heart 110.  The medical device 130 then enters then
left atrium (LA) 114 of the heart 110.  In one embodiment, the medical device 130 crosses the atrial septum 124 through a small atrial septostomy (created by cardiological techniques known in the art) to enter the left atrium 114 of the heart 110.  In
one embodiment, a guidewire (not shown) is placed across the atrial septostomy and the medical device 130 is threaded along the guidewire and into the left atrium 114.  The medical device 130 is stopped at a predetermined point in, at, or in proximity to
the mitral valve 120.  In one embodiment, the medical device 130 may have a preformed or deflectable short hook configuration at its tip region to facilitate the insertion of the medical device 130 into the mitral valve area.  Once the medical device 130
reaches the area in, at, or in proximity to mitral valve 120, the ligature 100 can be deployed as previous described and be placed across the mitral valve in similar manners as those shown in FIGS. 4-5.


FIG. 14B illustrates an exemplary route of percutaneously inserting the ligatures 100 into a patient's heart 110 to perform a ventricular remodeling of the heart.  In ventricular remodeling, the ligature (or ligatures) 100 can be used to reduce
the size of the ventricle by placing these ligatures around the left ventricle (which is typically the ventricle that is enlarged due to a faulty mechanism in the heart such as regurgitation).  With the ligatures 100 placed around the left ventricle, the
size of the left ventricle can be reduced, hence, remodeled.


Continuing with FIG. 14B, in one embodiment, a medical device 130 is first provided.  In one embodiment, the medical device 130 can be the medial device 301 or the medical device 302 described above.  In another embodiment, the medical device 130
can be a catheter capable of delivering and deploying a ligature 100 to the heart.  The medical device 130 is advanced up the inferior vena cava (IVC) 122 and into the right atrium (RA) 112 of the heart 110.  The medical device 130 then enters then left
atrium (LA) 114 of the heart 110.  In one embodiment, the medical device 130 crosses the atrial septum 124 through a small atrial septostomy (created by cardiological techniques known in the art) to enter the left atrium 114 of the heart 110.  In one
embodiment, a guidewire (not shown) is placed across the atrial septostomy and the medical device 130 is threaded along the guidewire and into the left atrium 114.  The medical device 130 is advanced through the mitral valve 120 to enter the left
ventricle 118.  In one embodiment, the medical device 130 may have a preformed or deflectable short hook configuration at its tip region to facilitate the insertion of the medical device 130 into the mitral valve area.  Once the medical device 130 is
inserted through the mitral valve 120, the ligature 100 can be deployed as previous described to anchor one of the anchoring members into the papillary muscles in the left ventricle 118 and the other anchoring member into a cardiac tissue opposite the
heart muscles.  This process is repeated to deploy several ligatures 100 as it may be necessary to employ more than one ligature to reduce the size of an enlarged left ventricle.  In one embodiment, after several ligatures 100 have been deployed, the
ligatures surround the left ventricle 118 as shown in FIG. 14B.


FIG. 14C illustrates another exemplary route of percutaneously inserting the ligatures 100 into a patient's heart 110 to perform a ventricular remodeling of the heart.  A medical device 130 is first provided.  In one embodiment, the medical
device 130 can be the medial device 301 or the medical device 302 described above.  In another embodiment, the medical device 130 can be a catheter capable of delivering and deploying a ligature 100 to the heart.  The medical device 130 is advanced up
the aorta 119 and directly into the left ventricle 118.  In one embodiment, the medical device 130 may have a preformed or deflectable short hook configuration at its tip region to facilitate the insertion of the medical device 130 into the left
ventricle 118.  Once the medical device 130 reaches the left ventricle 118, the ligature 100 is deployed as previous described to place the ligature 100 into the tissues of the left ventricle 118.  One such tissue is the heart muscles in the left
ventricle 118.  This process is repeated to deploy several ligatures 100 as it may be necessary to employ more than one ligature to reduce the size of an enlarged left ventricle.  In one embodiment, after several ligatures 100 have been deployed, the
ligatures span the interior of the left ventricle 118 as shown in FIG. 14C.


FIG. 15A illustrates an alternative embodiment of placing the ligature 100 around a mitral valve.  In this embodiment, the ligature 100 described previously is placed within the coronary sinus 212 of the heart 202.  The coronary sinus 212
substantially encircles the mitral valve annulus 206 of the mitral valve 204.  A first anchoring member of the ligature 100 (e.g., the first anchoring member 102A) extends outside one end of the coronary sinus 218 and anchors into the left fibrous
trigone 210.  A second anchoring member of the ligature 100 (e.g., the second anchoring member 102B) extends outside the coronary sinus 218 and anchors into the right fibrous trigone 200.  In one embodiment, the ligature 100 has a preformed shape such
that once the ligature 100 is deployed and that the first and the second anchoring members are anchored, the ligature 100 bends and reduces the radius of curvature of the coronary sinus 218.  In this embodiment, the ligature 100 can be made of a shape
memory material and may be flexible or rigid.  The ligature 100 may be made of a shape memory material such as Nitinol or other material that has a memory of an original shape as shown in FIG. 15B and can be temporarily stretched or forced into another
shape during deployment as shown in FIG. 15C and FIG. 15D.  Since the coronary sinus 218 substantially encircles the mitral valve annulus 206, the reduction of the radius of curvature of the bent coronary sinus 218 will result in a diameter and
circumference reduction of the mitral valve annulus 206.  In one embodiment the ligature 100 is surrounded or encapsulated by a jacket so as to prevent the ligature 100, once deployed within the coronary sinus 218, from cutting through the coronary sinus
218.


FIG. 16 illustrates an exemplary method 150 of treating a faulty heart valve by constricting or reducing the size of the heart valve.  At operation 152, a medical device such as the medical device 301 or 302 described above is provided.  At
operation 154, the ligature 100 is deployed into the patient wherein the first deployment shaft (e.g., the deployment shaft 310A, or 307) deploys the first anchoring member (e.g., the anchoring member 102A or 104A) to a first tissue area around the heart
valve and the second deployment shaft (e.g., the deployment shaft 310B, or 309) deploys the second anchoring member (e.g., the anchoring member 102B or 104B) to a second tissue area of the heart valve.  The ligature 100 can be deployed using the
embodiments previously described.  Deploying the ligature 100 anchors the first anchoring member to the first tissue area and the second anchoring member to the second tissue area as described above.  The method 150 can be repeated in embodiments where
multiple ligatures 100 are to be placed across the heart valve.  The number of ligatures 100 sufficient to treat a faulty heart valve depends on how much of the size of the faulty heart valve needs to be constricted or reduced.  The cross section size of
each of the ligatures 100 is sufficiently small so as to not cause thrombus or to not significantly impede the blood flow through the heart valve.  The length of each of the ligatures 100 can be varied depending on the area the ligature 100 needs to
constrict or reduce.


The percutaneous methods described above can be used to place the ligature(s) 100 across the mitral valve to constrict (or reduce) the size of a faulty or defective heart valve.  In one embodiment, the ligatures 100 are placed across the mitral
valve in order to prevent back flow of blood that a patient with a regurgitation condition caused by a faulty mitral valve would experience.  The described medical devices including the ligatures 100 that enable percutaneous introduction of the ligatures
100 into patients can replace those cases that require surgical procedures to reduce or constrict the mitral valve.  Such a percutaneous method also reduces patient discomfort, improves recovery time, and reduces hospitalization time relatives to a
surgical procedure in which the chest is opened.


* * * * *























								
To top